Abstract
Background Fentanyl is a synthetic opioid that is commonly given as a medication to alleviate pain. This drug can be administered through multiple routes, hence making it easy to exploit at high rates. Due to the flexibility in which it can be taken, it increases the ease of both access and use. The purpose of this study was to analyze trends in the distribution of fentanyl and its formulations across Medicaid enrollees in California and among the 3-digit registrant zip codes in California over the period of pre-pandemic (2018–2019) to the early stages of the COVID-19 pandemic (2020).
Methods Using the Automated Reports and Consolidated Ordering System (ARCOS), the distribution of fentanyl across California was compiled from 2018 to 2020. Utilizing ARCOS, the number of individuals within the source population who lived in one of California’s many zip codes was observed. To analyze the fentanyl distribution trend, we used Google Sheets, GraphPad Prism (Version 9.3.0 [463]), and Microsoft 365 Excel. These were helpful to organize the Medicaid, ARCOS data, and as well as to create graphs. The Medicaid database was used to compile the number of fentanyl formulations prescribed from 2018 to 2020 across California.
Results The analyses from both databases provided insight into the difference in fentanyl distribution in California from the years 2018 to 2020. After looking further into the many 3-digit registrant zip codes as well as Medicaid enrollees, it was found that there was a decrease in the distribution of fentanyl and its formulations. Additionally, it was found that the distribution of fentanyl as a medication by business activities also decreased from 2018 to 2020.
Conclusion The results indicate that there was more fentanyl being distributed and prescribed before the pandemic (2018– 2019). On the other hand, when we considered the effects of the pandemic, during 2020, there was quite a drastic decrease in the amount of fentanyl being prescribed and distributed to those living in California and those enrolled in Medicaid.
Competing Interest Statement
BJP was part of an osteoarthritis team from 2019–2021 supported by Pfizer and Eli Lilly. The other authors disclose no conflicts of interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html. https://www.deadiversion.usdoj.gov/arcos/index.html.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Master of Biomedical Sciences Program
Data Availability
All data produced in the present study are contained in the manuscript.
